Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells 307 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now directly owns 1,627 shares of the company's stock, valued at $899,275.44. The trade was a 15.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Axon Enterprise Stock Performance

Axon Enterprise stock traded up $1.59 during mid-day trading on Friday, reaching $560.00. 802,214 shares of the company traded hands, compared to its average volume of 845,276. The firm's fifty day moving average is $591.90 and its two-hundred day moving average is $542.26. The company has a market capitalization of $42.91 billion, a price-to-earnings ratio of 144.70, a price-to-earnings-growth ratio of 5.17 and a beta of 1.12. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $715.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds have recently made changes to their positions in the company. 111 Capital acquired a new stake in Axon Enterprise during the 4th quarter worth about $280,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Axon Enterprise by 36.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,932 shares of the biotechnology company's stock worth $10,063,000 after purchasing an additional 4,510 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in shares of Axon Enterprise during the fourth quarter worth about $13,986,000. Centaurus Financial Inc. boosted its position in Axon Enterprise by 43.9% in the fourth quarter. Centaurus Financial Inc. now owns 6,517 shares of the biotechnology company's stock valued at $3,873,000 after buying an additional 1,989 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC acquired a new position in Axon Enterprise in the 4th quarter worth approximately $1,677,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several analysts have issued reports on AXON shares. The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Barclays reissued a "hold" rating on shares of Axon Enterprise in a research note on Monday, March 10th. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Finally, Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $604.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.